Annual EBITDA
-$29.26 M
+$4.96 M+14.51%
December 31, 2023
Summary
- As of February 23, 2025, VYNE annual EBITDA is -$29.26 million, with the most recent change of +$4.96 million (+14.51%) on December 31, 2023.
- During the last 3 years, VYNE annual EBITDA has risen by +$221.84 million (+88.35%).
- VYNE annual EBITDA is now -534.94% below its all-time high of -$4.61 million, reached on December 31, 2015.
Performance
VYNE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$13.09 M
-$2.69 M-25.92%
September 30, 2024
Summary
- As of February 23, 2025, VYNE quarterly EBITDA is -$13.09 million, with the most recent change of -$2.69 million (-25.92%) on September 30, 2024.
- Over the past year, VYNE quarterly EBITDA has stayed the same.
- VYNE quarterly EBITDA is now -165.92% below its all-time high of -$4.92 million, reached on December 31, 2016.
Performance
VYNE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$37.70 M
-$6.86 M-22.23%
September 30, 2024
Summary
- As of February 23, 2025, VYNE TTM EBITDA is -$37.70 million, with the most recent change of -$6.86 million (-22.23%) on September 30, 2024.
- Over the past year, VYNE TTM EBITDA has stayed the same.
- VYNE TTM EBITDA is now -665.77% below its all-time high of -$4.92 million, reached on December 31, 2016.
Performance
VYNE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VYNE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.5% | 0.0% | 0.0% |
| 3 y3 years | +88.3% | 0.0% | 0.0% |
| 5 y5 years | +46.3% | 0.0% | 0.0% |
VYNE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +24.9% | -122.8% | at low | -28.9% | +3.2% |
| 5 y | 5-year | at high | +88.3% | -122.8% | +92.1% | -28.9% | +85.0% |
| alltime | all time | -534.9% | +88.3% | -165.9% | +92.1% | -665.8% | +85.0% |
VYNE Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$13.09 M(+25.9%) | -$37.70 M(+22.2%) |
| Jun 2024 | - | -$10.40 M(+40.9%) | -$30.84 M(+0.3%) |
| Mar 2024 | - | -$7.38 M(+8.0%) | -$30.76 M(+5.1%) |
| Dec 2023 | -$29.26 M(-14.5%) | -$6.83 M(+9.6%) | -$29.26 M(-3.8%) |
| Sep 2023 | - | -$6.23 M(-39.6%) | -$30.41 M(-8.8%) |
| Jun 2023 | - | -$10.32 M(+75.6%) | -$33.34 M(+6.5%) |
| Mar 2023 | - | -$5.88 M(-26.4%) | -$31.30 M(-8.1%) |
| Dec 2022 | -$34.22 M(-12.1%) | -$7.98 M(-12.9%) | -$34.07 M(-2.3%) |
| Sep 2022 | - | -$9.16 M(+10.7%) | -$34.88 M(-4.4%) |
| Jun 2022 | - | -$8.28 M(-4.3%) | -$36.49 M(-3.5%) |
| Mar 2022 | - | -$8.65 M(-1.7%) | -$37.80 M(-2.9%) |
| Dec 2021 | -$38.94 M(-84.5%) | -$8.79 M(-18.4%) | -$38.94 M(-25.2%) |
| Sep 2021 | - | -$10.77 M(+12.4%) | -$52.08 M(-19.7%) |
| Jun 2021 | - | -$9.58 M(-2.1%) | -$64.86 M(-70.8%) |
| Mar 2021 | - | -$9.79 M(-55.4%) | -$221.81 M(-11.7%) |
| Dec 2020 | -$251.09 M | -$21.93 M(-6.9%) | -$251.09 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$23.55 M(-85.9%) | -$250.92 M(+2.6%) |
| Jun 2020 | - | -$166.53 M(+326.2%) | -$244.62 M(+157.1%) |
| Mar 2020 | - | -$39.07 M(+79.6%) | -$95.14 M(+25.9%) |
| Dec 2019 | -$75.54 M(+38.6%) | -$21.76 M(+26.1%) | -$75.54 M(+4.6%) |
| Sep 2019 | - | -$17.26 M(+1.2%) | -$72.21 M(+5.2%) |
| Jun 2019 | - | -$17.05 M(-12.5%) | -$68.65 M(+13.0%) |
| Mar 2019 | - | -$19.48 M(+5.7%) | -$60.78 M(+11.5%) |
| Dec 2018 | -$54.51 M(+84.3%) | -$18.43 M(+34.5%) | -$54.51 M(+19.7%) |
| Sep 2018 | - | -$13.70 M(+49.3%) | -$45.56 M(+13.3%) |
| Jun 2018 | - | -$9.17 M(-30.6%) | -$40.20 M(+7.9%) |
| Mar 2018 | - | -$13.21 M(+39.5%) | -$37.25 M(+25.9%) |
| Dec 2017 | -$29.59 M(+106.5%) | -$9.47 M(+13.7%) | -$29.58 M(+18.2%) |
| Sep 2017 | - | -$8.33 M(+33.9%) | -$25.03 M(+49.9%) |
| Jun 2017 | - | -$6.22 M(+12.1%) | -$16.70 M(+59.4%) |
| Mar 2017 | - | -$5.55 M(+12.8%) | -$10.48 M(+112.8%) |
| Dec 2016 | -$14.33 M(+210.9%) | -$4.92 M | -$4.92 M |
| Dec 2015 | -$4.61 M | - | - |
FAQ
- What is VYNE Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for VYNE Therapeutics?
- What is VYNE Therapeutics annual EBITDA year-on-year change?
- What is VYNE Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly EBITDA year-on-year change?
- What is VYNE Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for VYNE Therapeutics?
- What is VYNE Therapeutics TTM EBITDA year-on-year change?
What is VYNE Therapeutics annual EBITDA?
The current annual EBITDA of VYNE is -$29.26 M
What is the all time high annual EBITDA for VYNE Therapeutics?
VYNE Therapeutics all-time high annual EBITDA is -$4.61 M
What is VYNE Therapeutics annual EBITDA year-on-year change?
Over the past year, VYNE annual EBITDA has changed by +$4.96 M (+14.51%)
What is VYNE Therapeutics quarterly EBITDA?
The current quarterly EBITDA of VYNE is -$13.09 M
What is the all time high quarterly EBITDA for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly EBITDA is -$4.92 M
What is VYNE Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VYNE quarterly EBITDA has changed by $0.00 (0.00%)
What is VYNE Therapeutics TTM EBITDA?
The current TTM EBITDA of VYNE is -$37.70 M
What is the all time high TTM EBITDA for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM EBITDA is -$4.92 M
What is VYNE Therapeutics TTM EBITDA year-on-year change?
Over the past year, VYNE TTM EBITDA has changed by $0.00 (0.00%)